Johnson & Johnson (NYSE:JNJ) EVP Vanessa Broadhurst Sells 6,197 Shares

February 19, 2026 by InsiderTrades.com

Johnson & Johnson (NYSE:JNJ - Get Free Report) EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Johnson & Johnson Stock Performance

5 Stocks and ETFs to Help Shield Your Portfolio During Volatility

Shares of Johnson & Johnson stock opened at $244.89 on Thursday. The business has a 50-day simple moving average of $219.71 and a 200-day simple moving average of $198.21. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a one year low of $141.50 and a one year high of $246.35. The company has a market cap of $590.17 billion, a PE ratio of 22.16, a P/E/G ratio of 2.36 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion during the quarter. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson's dividend payout ratio is 47.06%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Announced a >$1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Pennsylvania as part of a multi‑year U.S. manufacturing expansion, signaling long‑term capacity growth for its biologics/cell therapy pipeline. Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
Positive Sentiment: FDA approved a simplified monthly dosing schedule for RYBREVANT FASPRO (amivantamab + hyaluronidase), improving convenience for EGFR+ NSCLC patients and potentially boosting uptake and product competitiveness. FDA approves RYBREVANT FASPRO as the only EGFR-targeted therapy that can be administered once a month
Positive Sentiment: Received FDA Breakthrough Therapy Designation for subcutaneous amivantamab (RYBREVANT FASPRO) in advanced head & neck cancer — a regulatory accelerator that can shorten development timelines and enhance commercial prospects if confirmatory data follow. RYBREVANT FASPRO receives U.S. FDA Breakthrough Therapy Designation for head and neck cancer
Positive Sentiment: Reinforced shareholder returns with a quarterly dividend increase (quarterly payout raised to $1.30), supporting JNJ’s income appeal and dividend‑investor base. Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?
Neutral Sentiment: Options activity has picked up interest around JNJ, which can amplify near‑term moves but doesn’t by itself change fundamentals. Watch for large/ directionally concentrated trades. Behind the Scenes of Johnson & Johnson's Latest Options Trends
Neutral Sentiment: Street attention and analyst writeups (Zacks, TipRanks) are keeping JNJ in the spotlight; useful for sentiment tracking but incremental to fundamental drivers. Johnson & Johnson (JNJ) Is a Trending Stock
Neutral Sentiment: A small contract extension with Trellus Health keeps an adherence/support program in place; operationally positive but immaterial to JNJ’s top line. Trellus Health shares double on J&J extension
Negative Sentiment: Ongoing talc litigation and recent verdict coverage continue to highlight legal risk and valuation uncertainty, which can cap multiple expansion despite operational positives. Johnson And Johnson Talc Verdict Puts Legal Risks And Valuation In Focus

Hedge Funds Weigh In On Johnson & Johnson

Johnson & Johnson Quietly Triggers a Trend Following Buy Signal

A number of hedge funds have recently modified their holdings of JNJ. Norges Bank acquired a new position in Johnson & Johnson in the fourth quarter valued at $6,924,523,000. Capital World Investors purchased a new stake in Johnson & Johnson during the 4th quarter valued at approximately $2,005,942,000. Laurel Wealth Advisors LLC lifted its position in Johnson & Johnson by 15,040.6% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company's stock worth $1,133,512,000 after acquiring an additional 7,371,687 shares during the period. Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock valued at $49,740,362,000 after purchasing an additional 3,731,074 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Johnson & Johnson by 41.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,423,886 shares of the company's stock valued at $2,571,124,000 after purchasing an additional 3,655,754 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Daiwa Securities Group upped their price objective on Johnson & Johnson from $203.00 to $237.00 and gave the stock an "outperform" rating in a research report on Thursday, January 29th. Morgan Stanley set a $262.00 target price on Johnson & Johnson and gave the stock an "overweight" rating in a research note on Wednesday, January 28th. Argus increased their price target on shares of Johnson & Johnson from $210.00 to $240.00 in a research note on Friday, January 23rd. Sanford C. Bernstein boosted their price objective on shares of Johnson & Johnson from $208.00 to $225.00 and gave the stock a "market perform" rating in a research report on Friday, January 23rd. Finally, Barclays upped their target price on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an "equal weight" rating in a report on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $233.73.

View Our Latest Analysis on JNJ

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.